罗格列酮对代谢综合征患者冠状动脉介入治疗术后的影响

Effect of rosiglitazone on the patients with metabolic syndrome after coronary intervention influence

目的观察罗格列酮对代谢综合征患者冠状动脉介入治疗(PCI)术后再狭窄率及代谢指标的影响。方法随机分成对照组(按常规治疗)和罗格列酮组(常规治疗+罗格列酮治疗),在行PCI术前1d,罗格列酮组患者在原来用药的基础上予罗格列酮8mg,poqd,以后以4mgd治疗;对照组采用原来药物治疗,不加用罗格列酮。两组患者术后常规随访6个月。结果罗格列酮组升高了HDL-C,降低了TG、CRP,有统计学意义(P<0.05);有降低PCI术后支架内再狭窄率趋势;未增加不良心血管事件发生率。结论罗格列酮能改善代谢综合征患者的血糖、血脂代谢指标,并可减轻炎症反应,有益于减少PCI术后支架内再狭窄。

Objective Rosiglitazone on metabolic syndrome coronary intervention（ PCI） restenosis rate and metabolic indexes. Methods Randomly divided into control group（ according to conventional treatment） and rosiglitazone group（ conventional therapy ＋ rosiglitazone） ,preoperative PCI line 1 d,rosiglitazone patients on the basis of the original drug to rosiglitazone 8 mg,po qd,later to 4 mg/d treatment; the control group,the original medication,without rosiglitazone. Two groups of patients received postoperative routine follow-up 6 mo. Results Rosiglitazone group had increased HDL-C,lower TG,CRP,there was significant（ P 0. 05） ; have reduced in-stent restenosis after PCI rate trends; not increase the incidence of adverse cardiovascular events. Conclusion Rosiglitazone in patients with metabolic syndrome can improve blood glucose and lipid metabolism,and reduce the inflammatory response,also reduce in-stent restenosis after PCI.